Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial
Author:
Funder
Boehringer Ingelheim
Eli Lilly and Company
AstraZeneca
Daiichi-Sankyo
Eisai
Janssen
Novo Nordisk
Sanofi
Intarcia
Merck
Lilly
Mitsubishi
Publisher
Elsevier BV
Subject
Nephrology
Reference8 articles.
1. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014;Afkarian;JAMA,2016
2. Kidney disease and increased mortality risk in type 2 diabetes;Afkarian;J Am Soc Nephrol,2013
3. Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes;Molitch;Kidney Int,2015
4. The effect of RAAS blockade on the progression of diabetic nephropathy;Roscioni;Nat Rev Nephrol,2014
5. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015
Cited by 35 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. ‘We are somehow fixated on this being a diabetes drug’: a qualitative study exploring the views of cardiologists and nephrologists about sodium‐glucose cotransporter 2 inhibitor initiation;Internal Medicine Journal;2023-08-07
2. The efficacy and safety of SGLT2 inhibitors in patients with non-diabetic chronic kidney disease: a systematic review and meta-analysis;International Urology and Nephrology;2023-04-13
3. Sodium–glucose cotransporter inhibitors and kidney fibrosis: review of the current evidence and related mechanisms;Pharmacological Reports;2022-12-19
4. Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes;Cardiovascular Diabetology;2022-08-04
5. Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58;Diabetes Care;2022-01-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3